Arrowhead Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. both aim to bring their first wholly owned drugs to market for the treatment of familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), with Ionis’s olezarsen in the leading position. But Arrowhead outlined a new plan to focus all of its late-stage cardiovascular disease development efforts on its FCS and SHTG drug plozasiran, which means the company will seek a partner to pursue Phase III development of its other late-stage cardiovascular candidate, zodasiran.
Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis
Drug May Reach Market In 2025, After Olezarsen
Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.
More from Cardiovascular
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus